Pamela C. Egan

Pamela C. Egan

Auto-generated profile, based on publicly available information

Pamela C. Egan

Department of Medicine, The Warren Alpert Medical School of Brown University, Providence, RI 02903, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2018 in Blood
Verified
Journal Article
Closed access
PDF file
TLThomas W. LeBlanc
Thomas W. LeBlanc
PEPamela C. Egan
Pamela C. Egan
AOAdam J. Olszewski
Adam J. Olszewski
Key Points: Transfusion-dependent Medicare patients with leukemia had a 51% shorter duration of hospice stay, indicating a barrier to timely referral. Use of hospice in leukemia has increased and is associated with improved quality measures, regardless of transfusion dependence.

7 August 2020 in Blood Advances
Verified
Journal Article
Open access
PDF file
PEPamela C. Egan
Pamela C. Egan
TLThomas W. LeBlanc
Thomas W. LeBlanc
AOAdam J. Olszewski
Adam J. Olszewski
Patients with hematologic malignancies are thought to receive more aggressive end-of-life (EOL) care and have suboptimal hospice use compared with patients with solid tumors, but descriptions of EOL outcomes from comprehensive cohorts have been lacking. We used the population-based Surveillance, Epidemiology, and End Results–Medicare dataset to describe hospice use and indicators of aggressive EOL care among Medicare beneficiaries who died of hematologic malignancies in 2008-2015. Overall, 56.5% of decedents used hospice services for median 9 days (interquartile range, 3-27), 33.0% died in an acute hospital setting, 36.8% had an intensive care unit (ICU) admission in the last 30 days of life, and 13.3% received chemotherapy within the last 14 days of life. Hospice use was associated with 96% lower probability of inpatient death (adjusted risk ratio [aRR], 0.038; 95% confidence interval [CI], 0.035-0.042), 44% lower probability of an ICU stay in the last 30 days of life (aRR, 0.56; 95% CI, 0.54-0.57), and 62% decrease in chemotherapy use in the last 14 days of life (aRR, 0.38; 95% CI, 0.35-0.41). Hospice enrollees spent on average 41% fewer days as inpatient during the last month of life (adjusted means ratio, 0.59; 95% CI, 0.57-0.60) and had 38% lower mean Medicare spending in the last month of life (adjusted means ratio, 0.62; 95% CI, 0.61-0.64). These associations were consistent across histologic subgroups. In conclusion, EOL care quality outcomes and hospice enrollment were suboptimal among older decedents with hematologic cancers, but hospice use was associated with a consistent decrease in aggressive care at EOL.

11 March 2026 in Blood Advances
Verified
Journal Article
Open access
MSMikkael A. Sekeres
Mikkael A. Sekeres
RMRyan Mattison
Ryan Mattison
AAAndrew Artz
Andrew Artz
BRBaer M R
Baer M R
CCChong Chyn Chua
Chong Chyn Chua
RBRomina Brignardello-Petersen
Romina Brignardello-Petersen
Background: Older adults with acute myeloid leukemia (AML) represent a cancer population in which disease-based risk factors, comorbidities, patient goals, and treatment risks and benefits influence treatment recommendations. Objective: These evidence-based guidelines from the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health professionals in their decisions about management of AML in older adults. Methods: ASH formed a multidisciplinary guideline panel, including patient representatives, that minimized bias from conflicts of interest. Clarity Research Group at McMaster University supported the guideline development process, including updating or performing systematic evidence reviews. The panel prioritized questions and outcomes according to their importance for clinicians and patients. The panel used the grading of recommendations assessment, development and evaluation approach, including evidence-to-decision frameworks, to assess evidence and make recommendations. Results: The panel agreed on 9 critical clinical recommendations for managing AML in older adults, mirroring real-time practitioner-patient conversations: the decision to pursue antileukemic treatment vs best supportive management; traditional induction and postremission therapy vs hypomethylating agent or low-dose cytarabine, or combinations with venetoclax; the role and duration of postremission therapy; combinations with venetoclax vs monotherapy; the use of targeted therapy, including isocitrate dehydrogenase and FMS-like tyrosine kinase 3 (FLT3) inhibitors, in appropriate patients; the role of hematopoietic stem cell transplantation in nonfavorable prognosis AML; and the role of transfusion support for patients no longer receiving antileukemic therapy. Conclusions: Key recommendations of these guidelines include treatment over best supportive care; venetoclax-based regimens over monotherapies; and incorporation of FLT3 inhibitors into traditional induction and postremission therapy.

21 August 2019 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
DDDominic P. Decker
Dominic P. Decker
PEPamela C. Egan
Pamela C. Egan
AZAdam Zayac
Adam Zayac
DTDiana O. Treaba
Diana O. Treaba
AOAdam J. Olszewski
Adam J. Olszewski
The 2016 World Health Organization (WHO) classification has designated two categories of high-grade B-cell lymphoma (HGBCL): HGBCL with MYC and BLC2 and/or BCL6 rearrangements (often referred to as...

30 March 2022 in Journal of Palliative Medicine
Verified
Journal Article
Closed access
APAri Pelcovits
Ari Pelcovits
AOAdam J. Olszewski
Adam J. Olszewski
DDDominic Decker
Dominic Decker
DGDana Guyer
Dana Guyer
TLThomas W. Leblanc
Thomas W. Leblanc
PEPamela Egan
Pamela Egan
Background: Patients with hematologic malignancies (HMs) receive more disease directed care at the end of life (EOL) and often die in the hospital. The impact of early palliative care (PC) consultation on EOL quality outcomes in HMs has not been well described. Objectives: In 2017 we embedded a PC specialist within our inpatient malignant hematology team at our hospital in Providence, Rhode Island to facilitate the use of early PC. We sought to determine if this practice was accompanied by a shift in EOL outcomes. Design/Setting: We conducted a retrospective review of patients diagnosed with acute myeloid leukemia (AML) at our institution in the two years before (Cohort A) and after (Cohort B) insertion of a PC specialist. We identified patients who received a PC consultation and whether it was early or late. We then examined EOL quality outcomes: hospitalizations and intensive care unit (ICU) admissions in the last 30 days of life, chemotherapy use in the last 14 days of life, use of hospice, and death out of hospital. Results: Among 139 AML patients, 46 in Cohort A and 93 in Cohort B, we identified 34 and 47 decedents in each cohort, respectively. There was no significant improvement in EOL outcomes between Cohort A and B or among patients receiving early PC ( p > 0.05); however, PC in general across all cohorts was associated with significant increase in hospice use and fewer ICU admissions ( p = 0.016 and 0.0043, respectively). Conclusion: Earlier PC consultation in AML was not significantly associated with improvement in EOL quality outcomes; however, PC use in general was with improvement in use of hospice and ICU utilization. Further studies are needed to more definitively examine the relationship between early PC and EOL outcomes in patients with HMs and to examine non EOL outcomes such as patient experience and quality-of-life measures.

13 January 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
CBCourtney Elizabeth Baird
Courtney Elizabeth Baird
EWElizabeth Wulff-Burchfield
Elizabeth Wulff-Burchfield
PEPamela C. Egan
Pamela C. Egan
LHLee A Hugar
Lee A Hugar
AVAmi Vyas
Ami Vyas
EBEmmanuelle Belanger
Emmanuelle Belanger
Purpose: Medicare patients who die from cancer are responsible for about 30% of annual Medicare spending, most of which occurs during the last 30 days of life. Yet, there are significant and persisting knowledge gaps regarding which factors contribute to this high-intensity EoL spending. To that end, we conducted a retrospective analysis of SEER-Medicare data to identify risk factors associated with high-intensity EoL spending among older adults who died of breast, prostate, lung, or colorectal cancer. Methods: We used multivariable linear regression to identify clinical, demographic, socioeconomic, and geographic characteristics associated with total inflation-adjusted Medicare spending in the last 30 days of life, including reimbursements for services provided in the inpatient and outpatient settings. Study subjects included U.S. Medicare beneficiaries aged 65 and older who died of breast, prostate, lung, or colorectal cancer between 2011 and 2015. Results: Among 59,355 decedents (49.2% female; 21.2% of non-White race/ethnicity), factors associated with greater EoL spending were increased comorbidity burden, female sex, Black race, other race/ethnicity, stage III and IV disease, living in a more populated county, and state subsidization of patient Medicare premiums. EoL spending was lower among older patients, patients living in the Midwest, South, and West, patients living in more rural areas, and patients with poor performance status. Results were largely consistent across cancer types. Conclusion: Our findings can inform targeted intervention development for patients with cancer who are at higher risk of high-intensity EoL spending, such as decision-support tools that facilitate referrals to palliative care for high-risk patients.